October 22, 2016 10:18 AM ET


Company Overview of Iroko Pharmaceuticals Inc.

Company Overview

Iroko Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the development and commercialization of nonsteroidal anti-inflammatory drug therapeutics for patients to moderate acute and chronic pain. It provides Indocin for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and acute gouty arthritis; and Aldomet to treat hypertension. The company’s products under development include Zorvolex, a formulation of diclofenac to treat acute pain in adult patients, as well as completed the Phase III clinical trials for the treatment of osteoarthritis pain; Tiforbex, a formulation of indomethacin that has completed the Phase III clini...

One Kew Place

150 Rouse Boulevard

Philadelphia, PA 19112

United States

Founded in 2012

71 Employees





Key Executives for Iroko Pharmaceuticals Inc.

Executive Chairman of the Board and Chief Executive Officer
Age: 54
Senior Vice President and Chief Financial Officer
Age: 69
Senior Vice President and General Counsel
Age: 49
Senior Vice President and Chief Medical Officer
Age: 60
Senior Vice President of Corporate Development and Alliance Management
Age: 56
Compensation as of Fiscal Year 2016.

Iroko Pharmaceuticals Inc. Key Developments

Iroko Pharmaceuticals Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-12-2016 11:45 AM

Iroko Pharmaceuticals Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-12-2016 11:45 AM. Venue: Le Parker Meridien, New York, New York, United States.

Iroko Pharmaceuticals, LLC Secures Debt Financing From CRG LP

Iroko Pharmaceuticals, LLC announced that the company has entered into a $140 million debt facility agreement with CRG LP to retire an existing debt facility and provide additional working capital for the company. Cantor Fitzgerald acted as the exclusive financial advisor to Iroko in this transaction.

Iroko Pharmaceuticals Inc. Enters into Licensing Agreement with Laboratorios Saval S.A

Iroko Pharmaceuticals Inc. announced that it has entered into a licensing agreement with LABORATORIOS SAVAL S.A. for the exclusive rights to market and sell ZORVOLEX® (diclofenac) capsules, in an additional five countries in South America. LABORATORIOS SAVAL S.A. will be responsible for obtaining regulatory and pricing approval as well as provide marketing and distribution in Bolivia, Chile, Ecuador, Paraguay and Peru.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Iroko Pharmaceuticals Inc., please visit www.iroko.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.